Clinical Research · global
CAR-T therapy shows early signals in multiple sclerosis as serious neurotoxicity and a death are disclosed
In an early trial involving 66 participants, disease activity and disability remained stable in some patients, but serious neurotoxicity and a fatal infection also mean that the potential benefits of a single cell infusion must be weighed against the risks of the overall treatment.
Could a single cell infusion allow patients with multiple sclerosis to go for an extended period without relying on ongoing medication? An early trial presented by Bristol Myers Squibb (BMS) on October 23 at MSToronto 2026 provided signals warranting further investigation, while also revealing serious safety concerns: one case of grade 4 neurotoxicity occurred, and another patient died from pneumonia with sepsis on day 44 after infusion.
The phase 1 trial, called Breakfree-2, is evaluating the investigational autologous CAR-T cell therapy zolacabtagene autoleucel (zola-cel, BMS-986353). The therapy engineers patients’ own T cells to recognize CD19, thereby depleting B cells and exploring the possibility of resetting the immune system. The treatment process includes cell collection, manufacturing, lymphodepletion, and then a single infusion; both its effects and its risks must be understood in the context of the entire process.
According to the company’s announcement and reporting by S&P Capital IQ, the data covered 66 participants, including 30 with highly active relapsing multiple sclerosis and 36 with progressive disease. Patients had previously received a median of two types of disease-modifying therapy but continued to experience disease activity or worsening disability. This is a dose-escalation study without a control group, primarily assessing safety, with efficacy as a secondary assessment.
All 60 participants treated at the second dose level were off disease-modifying therapy at their last follow-up, with nine followed for more than a year. Efficacy assessments came from smaller groups: among seven patients with highly active relapsing disease who had at least 26 weeks of follow-up and could be evaluated for “no evidence of disease activity,” six met that endpoint; among 24 evaluable patients with progressive disease, 22 had stable or improved disability, and all 24 had no new disease activity on magnetic resonance imaging. These results, with their different denominators, cannot be directly interpreted as success rates for the entire patient population.
Safety data showed that 28 of the 66 participants experienced cytokine release syndrome, mostly grade 1; five experienced immune effector cell-associated neurotoxicity syndrome (ICANS). One patient with progressive disease developed grade 4 ICANS, which resolved within four days after treatment with corticosteroids and anakinra. Although most events were transient and reversible, this severe reaction remains an important signal when assessing treatment risks.
A separate fatal event occurred after the data cutoff. According to the company, the patient with relapsing disease developed delayed-onset, non-ICANS motor symptoms after infusion that did not resolve with intermittent corticosteroids and intravenous immunoglobulin; the patient subsequently received high-dose cyclophosphamide, then developed pneumonia with sepsis and died the following day. Independent medical news outlet FDA Webview noted that BMS did not state whether investigators had determined that the death was directly related to zola-cel. The sequence of events alone is insufficient to establish a single cause.
The most pressing questions now are how long disease control can last and which patients face risks that could be offset by the potential benefits. Being off disease-modifying therapy does not in itself equate to durable remission; short-term stability in disability also cannot demonstrate that damaged nerves have been repaired. These interim conference data support continued research, but longer follow-up, a full safety analysis, and controlled trials are still needed to determine zola-cel’s place in the treatment of multiple sclerosis.